Genomic testing for pancreatic cancer in clinical practice as real-world evidence

Hideyuki Hayashi, Shigeki Tanishima, Kyoko Fujii, Ryo Mori, Yasunobu Okamura, Emmy Yanagita, Ryosuke Matsuoka, Toraji Amano, Ichiro Kinoshita, Yoshito Komatsu, Hirotoshi Dosaka-Akita, Hiroshi Nishihara

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Precision medicine guided by comprehensive genome sequencing represents a potential treatment strategy for pancreatic cancer. However, clinical sequencing for pancreatic cancer entails several practical difficulties. We have launched an in-house clinical sequencing system and started genomic testing for patients with cancer in clinical practice. We have analyzed the clinical utility of this system in pancreatic cancer. Methods: We retrospectively reviewed 20 patients with pancreatic cancer who visited our division. Genomic DNA was extracted from both tumor tissue and peripheral blood mononuclear cells obtained from the patients. We performed a comprehensive genomic testing using targeted amplicon sequencing for 160 cancer-related genes. The primary endpoints were the detection rates of potential actionable and druggable gene alterations. The secondary endpoints were the detection rate of secondary germline findings, the rate of re-biopsy required for genome sequencing, survival time after the initial visit (post-sequencing survival time), and turnaround time. Results: Although re-biopsy was required for 25% (5/20) of all patients, genomic testing was performed in all patients. Actionable and druggable gene alterations were detected in 100% (20/20) and 35% (7/20) of patients, respectively, whereas secondary germline findings were detected in 5% (1/20) of patients. The median turnaround times for physicians and patients were 20 and 26 days, respectively. The median post-sequencing survival time was 10.3 months. Only 10% (2/20) of all patients were treated with therapeutic agents based on the outcomes of genomic testing. Conclusions: The clinical application of comprehensive genomic testing for pancreatic cancer was feasible and promising in clinical practice.

Original languageEnglish
Pages (from-to)647-654
Number of pages8
JournalPancreatology
Volume18
Issue number6
DOIs
Publication statusPublished - 2018 Sep 1
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Survival
Genome
Biopsy
Precision Medicine
Neoplasm Genes
Genes
Blood Cells
Neoplasms
Physicians
DNA
Therapeutics

Keywords

  • Clinical sequencing
  • Gene alterations
  • Precision medicine
  • Turnaround time

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Genomic testing for pancreatic cancer in clinical practice as real-world evidence. / Hayashi, Hideyuki; Tanishima, Shigeki; Fujii, Kyoko; Mori, Ryo; Okamura, Yasunobu; Yanagita, Emmy; Matsuoka, Ryosuke; Amano, Toraji; Kinoshita, Ichiro; Komatsu, Yoshito; Dosaka-Akita, Hirotoshi; Nishihara, Hiroshi.

In: Pancreatology, Vol. 18, No. 6, 01.09.2018, p. 647-654.

Research output: Contribution to journalArticle

Hayashi, H, Tanishima, S, Fujii, K, Mori, R, Okamura, Y, Yanagita, E, Matsuoka, R, Amano, T, Kinoshita, I, Komatsu, Y, Dosaka-Akita, H & Nishihara, H 2018, 'Genomic testing for pancreatic cancer in clinical practice as real-world evidence', Pancreatology, vol. 18, no. 6, pp. 647-654. https://doi.org/10.1016/j.pan.2018.07.006
Hayashi, Hideyuki ; Tanishima, Shigeki ; Fujii, Kyoko ; Mori, Ryo ; Okamura, Yasunobu ; Yanagita, Emmy ; Matsuoka, Ryosuke ; Amano, Toraji ; Kinoshita, Ichiro ; Komatsu, Yoshito ; Dosaka-Akita, Hirotoshi ; Nishihara, Hiroshi. / Genomic testing for pancreatic cancer in clinical practice as real-world evidence. In: Pancreatology. 2018 ; Vol. 18, No. 6. pp. 647-654.
@article{6b258e5f75de4657b612df12a14c0eec,
title = "Genomic testing for pancreatic cancer in clinical practice as real-world evidence",
abstract = "Background: Precision medicine guided by comprehensive genome sequencing represents a potential treatment strategy for pancreatic cancer. However, clinical sequencing for pancreatic cancer entails several practical difficulties. We have launched an in-house clinical sequencing system and started genomic testing for patients with cancer in clinical practice. We have analyzed the clinical utility of this system in pancreatic cancer. Methods: We retrospectively reviewed 20 patients with pancreatic cancer who visited our division. Genomic DNA was extracted from both tumor tissue and peripheral blood mononuclear cells obtained from the patients. We performed a comprehensive genomic testing using targeted amplicon sequencing for 160 cancer-related genes. The primary endpoints were the detection rates of potential actionable and druggable gene alterations. The secondary endpoints were the detection rate of secondary germline findings, the rate of re-biopsy required for genome sequencing, survival time after the initial visit (post-sequencing survival time), and turnaround time. Results: Although re-biopsy was required for 25{\%} (5/20) of all patients, genomic testing was performed in all patients. Actionable and druggable gene alterations were detected in 100{\%} (20/20) and 35{\%} (7/20) of patients, respectively, whereas secondary germline findings were detected in 5{\%} (1/20) of patients. The median turnaround times for physicians and patients were 20 and 26 days, respectively. The median post-sequencing survival time was 10.3 months. Only 10{\%} (2/20) of all patients were treated with therapeutic agents based on the outcomes of genomic testing. Conclusions: The clinical application of comprehensive genomic testing for pancreatic cancer was feasible and promising in clinical practice.",
keywords = "Clinical sequencing, Gene alterations, Precision medicine, Turnaround time",
author = "Hideyuki Hayashi and Shigeki Tanishima and Kyoko Fujii and Ryo Mori and Yasunobu Okamura and Emmy Yanagita and Ryosuke Matsuoka and Toraji Amano and Ichiro Kinoshita and Yoshito Komatsu and Hirotoshi Dosaka-Akita and Hiroshi Nishihara",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.pan.2018.07.006",
language = "English",
volume = "18",
pages = "647--654",
journal = "Pancreatology",
issn = "1424-3903",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Genomic testing for pancreatic cancer in clinical practice as real-world evidence

AU - Hayashi, Hideyuki

AU - Tanishima, Shigeki

AU - Fujii, Kyoko

AU - Mori, Ryo

AU - Okamura, Yasunobu

AU - Yanagita, Emmy

AU - Matsuoka, Ryosuke

AU - Amano, Toraji

AU - Kinoshita, Ichiro

AU - Komatsu, Yoshito

AU - Dosaka-Akita, Hirotoshi

AU - Nishihara, Hiroshi

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background: Precision medicine guided by comprehensive genome sequencing represents a potential treatment strategy for pancreatic cancer. However, clinical sequencing for pancreatic cancer entails several practical difficulties. We have launched an in-house clinical sequencing system and started genomic testing for patients with cancer in clinical practice. We have analyzed the clinical utility of this system in pancreatic cancer. Methods: We retrospectively reviewed 20 patients with pancreatic cancer who visited our division. Genomic DNA was extracted from both tumor tissue and peripheral blood mononuclear cells obtained from the patients. We performed a comprehensive genomic testing using targeted amplicon sequencing for 160 cancer-related genes. The primary endpoints were the detection rates of potential actionable and druggable gene alterations. The secondary endpoints were the detection rate of secondary germline findings, the rate of re-biopsy required for genome sequencing, survival time after the initial visit (post-sequencing survival time), and turnaround time. Results: Although re-biopsy was required for 25% (5/20) of all patients, genomic testing was performed in all patients. Actionable and druggable gene alterations were detected in 100% (20/20) and 35% (7/20) of patients, respectively, whereas secondary germline findings were detected in 5% (1/20) of patients. The median turnaround times for physicians and patients were 20 and 26 days, respectively. The median post-sequencing survival time was 10.3 months. Only 10% (2/20) of all patients were treated with therapeutic agents based on the outcomes of genomic testing. Conclusions: The clinical application of comprehensive genomic testing for pancreatic cancer was feasible and promising in clinical practice.

AB - Background: Precision medicine guided by comprehensive genome sequencing represents a potential treatment strategy for pancreatic cancer. However, clinical sequencing for pancreatic cancer entails several practical difficulties. We have launched an in-house clinical sequencing system and started genomic testing for patients with cancer in clinical practice. We have analyzed the clinical utility of this system in pancreatic cancer. Methods: We retrospectively reviewed 20 patients with pancreatic cancer who visited our division. Genomic DNA was extracted from both tumor tissue and peripheral blood mononuclear cells obtained from the patients. We performed a comprehensive genomic testing using targeted amplicon sequencing for 160 cancer-related genes. The primary endpoints were the detection rates of potential actionable and druggable gene alterations. The secondary endpoints were the detection rate of secondary germline findings, the rate of re-biopsy required for genome sequencing, survival time after the initial visit (post-sequencing survival time), and turnaround time. Results: Although re-biopsy was required for 25% (5/20) of all patients, genomic testing was performed in all patients. Actionable and druggable gene alterations were detected in 100% (20/20) and 35% (7/20) of patients, respectively, whereas secondary germline findings were detected in 5% (1/20) of patients. The median turnaround times for physicians and patients were 20 and 26 days, respectively. The median post-sequencing survival time was 10.3 months. Only 10% (2/20) of all patients were treated with therapeutic agents based on the outcomes of genomic testing. Conclusions: The clinical application of comprehensive genomic testing for pancreatic cancer was feasible and promising in clinical practice.

KW - Clinical sequencing

KW - Gene alterations

KW - Precision medicine

KW - Turnaround time

UR - http://www.scopus.com/inward/record.url?scp=85050346208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050346208&partnerID=8YFLogxK

U2 - 10.1016/j.pan.2018.07.006

DO - 10.1016/j.pan.2018.07.006

M3 - Article

C2 - 30055942

AN - SCOPUS:85050346208

VL - 18

SP - 647

EP - 654

JO - Pancreatology

JF - Pancreatology

SN - 1424-3903

IS - 6

ER -